ACADIA Pharmaceuticals Inc (NAS:ACAD)
$ 16.95 -0.42 (-2.42%) Market Cap: 2.89 Bil Enterprise Value: 2.37 Bil PE Ratio: 22.27 PB Ratio: 5.01 GF Score: 75/100

ACADIA Pharmaceuticals Inc at Needham Neuroscience Forum (Virtual) Transcript

Mar 16, 2022 / 07:20PM GMT
Release Date Price: $23.6 (+2.39%)
Ami Fadia
Needham & Company - Analyst

Okay, good afternoon, everyone. Welcome to the next session with ACADIA. It's my pleasure to be hosting Steve Davis, who is the CEO of the company as well as the Board member; and Serge Stankovic, who is the Head of R&D of the company. Serge brings a wealth of experience in multiple disciplines: neurology, psychiatry, oncology, cardiology and pain. So, we are looking forward to a rich discussion.

Before we move forward, I just wanted to remind our audience that if you have any questions that you would like me to ask the management team, feel free to send it over to me in the chat. With that, Steve, could you please kick us off with a few comments and overview of the company?

Steve Davis
ACADIA Pharmaceuticals Inc. - CEO

Yeah, thanks so much, Ami. Thanks for having us and thanks for each of you for joining. I'll start with just a little bit of level setting. To deliver on our mission, we are focused on three strategic pillars. The first is to drive growth of our NUPLAZID franchise in Parkinson's disease

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot